Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials
Sage Therapeutics has reported positive top-line results from two phase 3 clinical trials with its i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 20...
Continue Reading →
